Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference46 articles.
1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.
2. • Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomized, phase 2, open-label trial. Lancet. 2019;393(10185):2051–8 Randomized trial showing survival benefit with the incorporation of MDT into standard of care systemic therapy.
3. • Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumor for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial. Lancet. 2018;392(10162):2353–66 Randomized trial showing survival benefit to radiation to the prostate for low volume metastatic patients.
4. Gomez DR, Tang C, Zhang J, Jr. GRB, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, Phase II, Randomized Study. 2019;37(18):1558–1565.
5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献